In a Phase I trial, biomarkers seem to suggest the potential for a once or twice yearly dosing of Wave’s siRNA for weight ...

AbbVie's Rinvoq will have to come up against Pfizer’s prospective and Incyte’s approved JAK inhibitors in the non-segmental ...

Aditya Kotta discussed the biotech funding environment and market trends at OCTSC meeting, in San Diego, California, US. Credits: Athanasios Psimadis / Arena International. The biotech sector has ...

The app helps sites and patients stay synchronised, supporting compliance. Credit: SOMKID THONGDEE/Shutterstock.com. US-based software company Suvoda has launched a unified patient mobile app to ease ...

Thermo Fisher Scientific has reached a definitive agreement to purchase clinical trial endpoint data solutions provider ...

Despite ADX-629 meeting all its endpoints in a Phase II trial, Aldeyra is culling the asset as part of a pipeline ...

Zenas BioPharma’s investigational relapsing multiple sclerosis (RMS) asset, obexelimab, has met its primary endpoint in the Phase II MoonStone trial. Image credit: OksanaFedorchuk via Shutterstock.com ...

Analysts at GlobalData forecast that GCG/GLP-1RA mazdutide will become a blockbuster seller in China for Innovent by 2030.

BridgeBio’s stock was up after it announced the Phase III trial met its endpoints. Image credit: saepul_bahri / Shutterstock.com. BridgeBio Pharma will seek US approval of its limb-girdle muscular ...

Inhibrx’s DR5-targeting antibody has more than doubled PFS compared with placebo in a Phase II trial in chondrosarcoma, a rare bone cancer with no approved targeted therapies. Image credit: Kateryna ...

The data was announced during the 2025 North American Menopause Society (NAMS) Annual Meeting. Image credit: shisu_ka / Shutterstock.com. Entera Bio’s osteoporosis candidate for postmenopausal women ...